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Neuroethics of neuromarketing
Emily R. Murphy1,2y, Judy Illes1z and Peter B. Reiner1*
1
National Core for Neuroethics, University of British Columbia, Vancouver, BC, Canada
2
Center for Law and the Biosciences, Stanford Law School, Stanford, CA, USA
 Neuromarketing is upon us. Companies are springing up to offer their clients brain-based
information about consumer preferences, purporting to bypass focus groups and other
marketing research techniques on the premise that directly peering into a consumer’s
brain while viewing products or brands is a much better predictor of consumer behavior.
These technologies raise a range of ethical issues, which fall into two major categories:
(1) protection of various parties who may be harmed or exploited by the research,
marketing, and deployment of neuromarketing and (2) protection of consumer auto-
nomy if neuromarketing reaches a critical level of effectiveness. The former is straightfor-
ward. The latter may or may not be problematic depending upon whether the technology
can be considered to so effectively manipulate consumer behavior such that consumers
are not able to be aware of the subversion. We call this phenomenon stealth neuromar-
keting. Academics and companies using neuromarketing techniques should adopt a code
of ethics, which we propose here, to ensure beneficent and non-harmful use of the
technology in consideration of both categories of ethics concerns.
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Introduction
In 1957, the marketing executive James Vicary
announced that he had increased sales of food
and drink at a movie theater by secretly
flashing subliminal messages with the words
‘‘Drink Coca Cola’’ and ‘‘Eat Popcorn’’. The
study was never published and may have even
been a hoax (Karremans et al., 2006), but the
episode illustrates the public’s strong reaction
to covert manipulation. An article in The
Nation called it ‘‘the most alarming invention
since Mr. Gatling invented his gun’’ and The
New Yorker stated that ‘‘minds had been
entered and broken’’ (Moore, 1982). With
growing public understanding that the brain is
the mediator of behavior, the public’s reaction
to neuromarketing intrusions into their brains
may prove to be equally vigorous.
The term ‘‘neuromarketing’’ identifies a new
field of research championed by both aca-
demics and self-labeled companies using
advances in neuroscience that permit power-
ful insights into the human brain’s responses to
marketing stimuli (Renvoisé and Morin, 2007;
Senior et al., 2007). The goals of neuromarket-
ing studies are to obtain objective information
about the inner workings of the brains of
consumers without resorting to the subjective
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reports that have long been the mainstay of
marketing studies. Thus, neuromarketing pur-
ports to provide qualitatively different infor-
mation, ostensibly superior to that obtained by
traditional means, about the economically
valuable topic of consumer preferences.
There is, of course, nothing inherently
problematic about the use of scientific tech-
nology to advance commercial interests (Eaton
and Illes, 2007). But the use of technology that
probes the inner workings of the human
brain, especially beyond what one might
divulge in traditional behavioral testing,
raises substantial ethical issues. These concerns
fall into two major categories: (1) protection of
various parties who may be harmed or
exploited byneuromarketing and (2) protection
of consumer autonomy. The public outcry
in response to Vicary’s subliminal imagery
reflects a clear ethical boundary – the autonomy
violation produced intrinsic discomfort with
consumers having their preferences manipu-
lated when they did not and could not know as
much. A similar boundary can be drawn for
contemporary marketing, particularly when
informed by information gleaned from novel
neurotechnologies. Neuroethics, in proactively
dealingwith ethical issues unique to knowledge
about and manipulation of the human brain, is
well-positioned to offer guidance for beneficent
and non-harmful deployment of neuromarket-
ing techniques.
Wewill first briefly review the state of the art
and state of the market in neuromarketing.
The second section tackles current ethical
issues in neuromarketing, which apply irre-
spective of the technological capabilities. We
focus our discussion on potential harms
to research subjects, exploitation of vulner-
able niche populations, and the integrity of
business relationships, public trust, and con-
sumer confidence. The third section will
thoroughly explore the most substantial neu-
roethical concern associated with neuromar-
keting: the incursion on autonomy made by
neuromarketing if it achieves a level of
effectiveness that amounts to consumer coer-
cion. We conclude with pragmatic recommen-
dations: an ethical code to be adopted by the
neuromarketing industry to prevent harms and
preserve business integrity and consumer
trust.
The market for neuromarketing
Although the electroencephalography (EEG)
has been in use for the study of marketing
preferences for over 35 years (Krugman,
1971), there is little doubt that we have
entered a new age of neuromarketing in which
advanced technology is being used in unpre-
cedented ways to probe consumer prefer-
ences. A raft of peer-reviewed papers and
books have appeared in recent years in which
positron emission tomography (PET), func-
tional magnetic resonance imaging (fMRI) and
quantitative EEG analyses have been used to
assess consumer behavior (Smith et al., 2002;
Dickhaut et al., 2003; McClure et al., 2004;
Mast and Zaltman, 2005; Ahlert et al., 2006;
Knutson et al., 2007; Koenigs and Tranel,
2008; Plassmann et al., 2007; Renvoisé and
Morin, 2007; Schaefer and Rotte, 2007a, b). It
has already been anticipated that other
neuroimaging technologies such as magne-
toencephalography and cortical manipulation
with transcranial magnetic stimulation, as well
as combinations of modalities will be adopted
by ‘‘market researchers who wish to deploy a
specialized neuromarketing profile’’ (Senior
et al., 2007). We refer the reader interested in
details of each technology to the recent
overview by Senior et al. (2007) as well as
other papers in this Special Issue; different
neuroimaging techniques have strengths and
weaknesses in temporal and spatial resolution.
The choice of modality by neuromarketers will
no doubt be informed by a priori hypotheses
and pilot research about relevant brain areas
and activation patterns useful for predicting
actual consumer behavior.
The convergence of increased power in the
form of technology and advances in our
understanding of cognitive function has
emboldened some to make sweeping con-
clusions about the power of neuromarketing.
Indeed, at least ten commercial enterprises
have been established with the explicit
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objective of using these advanced technologies
to provide neuromarketing (Emsense, FKF
Applied Research, Lucid Systems, Neurofocus,
Neuroco, Neurosense Limited, OTOInsights,
Sales Brain, Sands Research, and Thought
Sciences) and at least one US patent has been
issued on the topic (Zaltman and Kosslyn,
2000). Neuromarketing studies have garnered
a great deal of attention from the public, with
extensive coverage in both the mainstream
press (Kelly, 2002; Roston, 2004; Greene,
2007; Haq, 2007; Park, 2007; Saletan, 2007;
Baker, 2008; Brainard, 2008) and internet
weblogs (Dooley, 2007). One study has even
cautioned against a ‘‘neurorealism’’ created by
press coverage of novel technologies and their
real or potential applications in society (Racine
et al., 2005).
Protection of vulnerable parties
in research, selling, and
representation of neuromarketing
We first consider a set of issues that merit
ethical analysis irrespective of whether the
most speculative claims of neuromarketing
hold up to rigorous scientific analysis. Ethical
development of neuromarketing requires
protection of the research subjects, respon-
sible business-to-business advertising, and
accurate representation of the state of the
art of the technology to the public. Each of
these duties can be ensconced in an industry-
wide code of ethics that we propose be
adopted by all researchers and vendors of
neuromarketing and enforced by a discerning
marketplace of neuromarketing consumers
doing business with companies voluntarily
adhering to the code of ethics. Not only would
adoption of a code of ethics be justified on
moral grounds, but it would also serve to
insulate this young and dynamic industry from
accusations of irresponsible behavior.
Human subjects’ protection
It is well established that federally funded
scientists working in academic, government,
and commercial settings have both ethical and
legal responsibilities to obtain informed con-
sent and protect the privacy of research
subjects whose brain function is probed with
imaging technologies, as per the Common Rule
(DHHS, 1991). The legal framework for such
privacy protection in the United States is
covered under PRIVACY RULE of the Department
of Health and Human Services (DHHS, 2005);
while this applies in some instances, it is
notable that such protections are apparently
absent when the subject is participating in a
study being carried out for marketing purposes
(Tovino, 2005). Thus standards for protecting
the privacy of individuals participating in
neuromarketing studies in the United States
are at the very least considerably comprom-
ised. In academic and medical research
centers, subjects volunteering to participate
in neuroimaging-based studies are protected
by Institutional Review Board guidelines,
which can include strict experimental guide-
lines because most imaging technologies
are considered to be FDA-regulated medical
devices (FDA, 1998). However, when moved
into commercialized and private enterprise,
such subject protections may not be present,
and the particularly loose restrictions sur-
rounding studies for marketing purposes are
especially worrying. Moreover, if new tech-
nologies are developed that fall outside the
purview of regulatory authorities, even these
protections may be lost. A key initiative for
neuroethics in neuromarketing is to develop
published codes of subject protections equal
to those required by academic and medical
research centers. fMRI, the most prevalent of
the neuromarketing imaging modalities, is
arguably a low-risk technology; nonetheless,
risks of various sorts are inherent in all brain-
imaging research and all subjects regardless of
the purpose of the study are deserving of
adequate protection and appropriate informed
consent procedures.
Even thornier than the issue of subject
protection is the notion that advanced tech-
nology in the neurosciences, in particular
fMRI, might allow invasion of the inner
sanctum of private thought. It bears repeating
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that such a breach is not possible today and
may or may not be technically achieved in the
future. Nonetheless, a vigorous discussion has
emerged regarding this possibility (Kulynych,
2002; Illes and Racine, 2005; Tovino, 2005;
Greely, 2006; Alpert, 2007; Appelbaum, 2007;
Illes, 2007; Tovino, 2007) and it is certainly
worth considering how society might manage
such information if it became technically
feasible.
Preventing exploitation of niche
populations
Special ethics review should be a minimum
standard for neuromarketing research that
either involves or targets vulnerable popu-
lations. Among the individuals that would fall
under this umbrella are persons (or family
members of persons) with neurological disease
or psychological disorders, children, and other
members of legally protected groups (Civil
Right Act (2008) 42 U.S.C.A. xx 2000e et seq.;
Coenen, 2007). While such ‘‘segmentation’’
and ‘‘target marketing’’ is standard business
practice in the marketing industry, there is a
fine line between target marketing and exploi-
tation (Sims, 1997). Our neuroethical concern is
about potential harms to vulnerable persons
as: (1) subjects in unregulated neuromarketing
research (introduced above), (2) targeted
populations who may be especially sensitive
to trumped-up claims of product effectiveness
based on information derived from advanced
neuroscience technologies, and (3) people
particularly exposed to ‘‘stealth neuromarket-
ing’’ techniques that such research and devel-
opment may produce (see below). Fortunately,
the prevention of such harms to vulnerable
persons aligns with profit motive, for as Sims
(1997) points out, when targeting a particular
market ‘‘maligns those it tries to serve,’’ it
undercuts its own business interests.
Responsible business-to-business
advertising and public representation
It is perhaps not surprising that neuromarketing
oversells its wares – an occupational hazard of
sorts. Independent critics have openly and quite
rightly condemned neuromarketing efforts that
overstate the benefits of the approach. The
editors of the high-impact journal Nature
Neuroscience succinctly reviewed the dangers
of over interpretation of neuromarketing results,
noting that the traditional skeptical approach of
scientific inquiry is being displaced by a wave of
media hype which suggests that fMRI ‘‘is on the
verge of creating advertising campaigns that we
will be unable to resist’’ (Editorial, 2004). In this
sense, neuromarketing represents just one
example of a more general problem in neuroi-
maging research – the question of the degree to
which results which are certainly fascinating
and worthy of continued attention can be used
to derive bona fide insights about the working
of the human brain (Illes and Racine, 2005), and,
with particular relevance to the claims of
neuromarketing, the accurate prediction of
human behavior. Business consumers of neuro-
marketing may find their advertising dollars
misspent if the technology does not live up to its
claims and pass the real-world test of accurate
prediction of actual consumer behavior. How-
ever, we are not overly concerned here with
business-to-business relationships; harms there
are primarily the potential for financial loss,
but are not inherently unethical (though they
may not meet industry standards of ‘‘truth-in-
advertising’’) (Frazier, 2007). However, poten-
tial for actual harm exists if such ‘‘neurohype’’
around the perceived capabilities of neuromar-
keting create fear, anxiety, or mistrust in the
general public.
Scientists working in the field of neurobiol-
ogy recognize the considerable challenge
involved in the translation of the brain’s
extraordinary connectivity – the human brain
is arguably the most complex biological organ
in the known universe, with tens of billions of
cells, each of which make thousands of
connections with other cells (Purves et al.,
2008) – into the complex repertoire of
behavior exhibited by humans. At the same
time, the general public finds color-coded
images of brains in action accompanied by
neuroscientific explanations to be particularly
persuasive (Dumit, 2003; McCabe and Castel,
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2007;Weisberg et al., 2008). This tension leads
to a situation where highly sophisticated
scientists, subject to both public adulation
and profit motive, are tempted to provide
simplistic answers to what in reality are highly
nuanced questions.
The neuromarketing field has already seen
egregious abuse of such information. In an op-
ed piece in the New York Times, a group of
academics and neuromarketers presented a
small body of unpublished data on the
results of an fMRI study of political preferences
of so-called ‘swing voters’ (Iacaboni et al.,
2007). The results were presented essentially
as de facto probes into the minds of their
subjects in one of the most widely read
newspapers in the world; for several days
after its publication, the article topped the
rankings of those most frequently emailed by
readers of the online version of the New York
Times. Given widespread concerns about
over-interpretation of fMRI data (Illes et al.,
2006b), it was notable that the op-ed piece
contained none of the qualifications that
would normally accompany a scholarly article
in a peer-reviewed journal. Academic col-
leagues responded with considerable outrage
in letters to the editor (Aron et al., 2007) and
most visibly in a scathing editorial in Nature
(Editorial, 2007). Incidents such as this draw
attention to the absence of a code of ethics for
responsible media – if not academic –
representation in the field of neuromarketing.
Such misrepresentation can do considerable
damage to the public trust of science and may
even generalize in public perception to create
anxieties about the perceived motivations of
neuroscientists conducting human neuroima-
ging research. In the current climate of
tightening public funds for basic research,
any such anxiety threatens the future of the
field, with potential harms to public health.
Academic and private sectors of neuroscience
research need to maintain close partnerships
and work together to promote public trust and
investment in neuroscience research. That
trust can be earned with forthright communi-
cation and full disclosure of risks, benefits, and
limitations of research findings.
Stealth neuromarketing
In our view, the most vexing of the issues
raised by neuromarketing is in the realm of
autonomy. One could argue that the essential
objective of marketing as a discipline is to
manipulate consumer behavior – effectively, a
‘‘soft’’ attack on autonomy. Moreover, many of
the traditional tools of marketing such as focus
groups and polls rely upon nuanced interpret-
ations of human psychology to draw con-
clusions about consumer behavior and then
use that information to inform marketing
decisions. The implicit question in the present
discussion is whether the new tools of
neuromarketing will provide sufficient insight
into human neural function to allow manip-
ulation of the brain such that the consumer
cannot detect the subterfuge and that such
manipulations result in the desired behavior in
at least some exposed persons. Such stealth
neuromarketing is not possible with current
technology, but if developed would represent
a major incursion on individual autonomy. In
this analysis, we deliberately consider a set of
issues that will only arise with developments in
technology that are yet to be realized and may
never come to fruition. Nonetheless, it is in the
best interest of all parties involved in the
discussion that these issues are considered
today rather than at some unspecified time-
point in the future, possibly in response to an
adverse event. To appreciate how stealth
neuromarketing may come to pass, we present
a short discourse on phenomena in which
decision-making and motivation occur without
explicit conscious awareness.
It is well established that cognition is not a
monolithic process but rather one with various
submodalities carrying out a variety of func-
tions, some of which have been reasonably
well delineated. Of relevance to the present
discussion are two well-studied phenomena in
cognitive neuroscience. The first is blindsight
(Weiskrantz, 1990), in which individuals with
damage to portions of their visual cortex
declare themselves unable to see objects
placed in the damaged portion of their visual
field, but when asked to guess are easily able to
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identify the object. These experiments unequi-
vocally demonstrate that there is a distinction
between perception and conscious awareness.
The second phenomenon is implicit learning
(Reber, 1993), in which normal subjects are
presented with seemingly random strings of
letters and asked to memorize them. Unknown
to the individuals is the fact that there is a set of
rules being employed, but their attention is
directed towards memorization in the first part
of the experiment. Later they are asked to
describe the rules, and after protesting that
they did not know there were any rules, they
are asked to guess. Remarkably, subjects
correctly identify the rules over 70% of the
time. A recent brief report in Science (Aarts
et al., 2008) takes these phenomena one step
further and demonstrates how subliminal
priming effects can actually motivate and
mobilize people to respond more quickly
and spend extra effort on a simple motor task.
The simple but elegant study provides evi-
dence for the ‘‘human capacity to rely on
mental processes in preparing and motivating
behavior outside of awareness’’ (Aarts et al.,
2008). As the authors note, such responses are
of considerable utility insofar as they prepare
individuals to react quickly as circumstances
necessitate; at the same time, subliminal
priming represents an additional step towards
realization of stealth neuromarketing.
If it is possible to carry out highly sophisti-
cated cognitive tasks such as visual perception
or understanding grammatical rules, as well as
to enhance motivation and mobilization of
voluntary action without the relevant neural
computation arising to the level of perceptual
awareness, then it follows that at some point in
the future insights from advanced technology in
the neurosciences might allow corporations,
governments and others to influence decisions
and actions regarding brand preferencewithout
the individual being aware of the subterfuge.
We would propose such an eventuality as the
sensible point at which the erosion of personal
autonomy becomes so substantial that one
might consider regulatory control, voluntary or
otherwise, to protect the citizenry from
unwanted intrusions on individual agency.
Recommendations
We conclude with a preliminary version of a
code of ethics that we recommend be adopted
by the neuromarketing industry. The over-
arching goal of this code of ethics is to promote
research and development, entrepreneurship,
and profitable enterprise alongside beneficent
and non-harmful use of neuroimaging techno-
logy at all stages of development, deployment,
and dissemination. These codes should be
discussed within the neuromarketing com-
munity with the advice of independent aca-
demic researchers working in the area of
neural correlates of decision-making, social
behavior, and consumer preferences, as well as
neuroethicists and professionals in marketing
industry ethics. Proactive development of such
guidelines within the professional community
will provide credibility and garner greater
acceptance than those that may be imposed
upon the field by regulatory bodies, especially
if they arise in response to adverse events (Illes
et al., 2003). Timeliness in this effort is critical
given the rapid pace of advancements in the
field.
 Protection of research subjects. Policies for
responsibly managing clinical findings,
including provision of sufficient subject pro-
tections, procedures for informed consent,
and explicit protocols for dealing with inci-
dental findings (Illes et al., 2006a) are a
requirement for any entity involved in brain
research. Furthermore, private companies
offering financial incentives for participation
in research studies significantly greater than
those offered in academic settings should be
cautious of undue influence of such incen-
tives, which may cross over into indirect
coercion. While most technologies used
by neuromarketing may be considered mini-
mal risk, subjects should be advised and
reminded of their right to withdraw from
any study for any reason, including minor
discomfort.
 Protection of vulnerable niche populations
from marketing exploitation. Policies for
research subjects’ protection should include
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additional ethics review for research done on
protected or potentially vulnerable subject
populations. In addition, neuromarketing-
influenced advertising targeted at specific
protected consumer groups should aim to
beneficently serve the special needs of the
population without marginalizing, malign-
ing, or otherwise causing harm, whether
psychosocial or financial in nature.
 Full disclosure of goals, risks, and benefits.
Disclosure can be achieved through the
publication of ethics principles that have
been adopted to protect the privacy and
autonomy of human subjects and consu-
mers. Publication infers all aspects of the
process from consent documents to report-
ing and advertising and applies to both writ-
ten and verbal communication.
 Accurate media and marketing representa-
tion. Neuromarketing companies bear the
burden of accurately representing their
wares in media and business-to-business
marketing materials. At a minimum, this
standard encompasses full disclosure of
scientific methods and measures of validity
in mass media formats such as invited
opinions, editorials, and news reports.
Adherence to a code of responsible com-
munication and truth-in-advertising will help
maintain a positive and trusting public per-
ception of brain science research as well as
promote development of effective technol-
ogies.
 Internal and external validity. Eaton and
Illes (2007) have outlined the challenges in
initial and sustained product validity in the
commercialization of any neurotechnology.
We extend their recommendations here
to any marketing product influenced by
neuromarketing research with particular
attention to the point that the validity ques-
tions ‘‘arise most acutely for neurotechnol-
ogy that can be deployed without a
regulatory gatekeeper, such as the FDA’’
(Eaton and Illes, 2007). At a minimum,
internal validity checks should ensure a suf-
ficiently comprehensive research database
to provide meaningful and effective results
to neuromarketing consumers. External and
sustained validity will require neuromark-
eters to align their product with changing
technologies and expanding neuroscience
knowledge. Maintenance of safety and effi-
cacy verification in any research, develop-
ment, and deployment of neuromarketing is
absolutely required.
These recommendations form the basis for
immediate and short-term action in the neuro-
marketing community and longer-term empiri-
cal research. Multidisciplinary collaboration
will enable efficient and positive progress
along this continuum.
In the 50 years since Vicary’s subliminal
imagery marketing stunt, interest in the possib-
ility that neuroscience might be used in the
service of a marketing agenda has remained
robust, with the current resurgence of interest
and proliferation of companies in the new
neuromarketing being noteworthy. It should
be emphasized that there is no evidence that at
the present time that any advanced neurotech-
nology permits the types of insights and sub-
sequent manipulation that Vicary envisaged
(Illes and Racine, 2005; Illes, 2007). However,
the fact that one must insert qualifiers such as
‘‘at the present time’’ provides ample reason to
carefully consider the implications that such a
development might have and the means by
which it might be sensibly managed. In the
meantime, there are a host of ethical issues in
the research, marketing, and deployment of
neuromarketing on the table right now. Such
proactive conduct is at the heart of the neu-
roethical agenda.
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